New ADCs bring new questions in EGFR NSCLC and beyond

Ann Oncol. 2024 May;35(5):412-413. doi: 10.1016/j.annonc.2024.03.004. Epub 2024 Mar 12.

Authors

S Scott¹, B Levy²

Affiliations

¹ Johns Hopkins School of Medicine, Baltimore; Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, USA.
² Johns Hopkins School of Medicine, Baltimore; Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, USA. Electronic address: Blevy11@jhmi.edu.

PMID: 38484972
DOI: 10.1016/j.annonc.2024.03.004

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors* / antagonists & inhibitors
ErbB Receptors* / genetics
Humans
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Antibodies, Monoclonal
EGFR protein, human
ErbB Receptors
Protein Kinase Inhibitors